Viatris (VTRS) Declares $0.12 Dividend
Viatris said on February 24, 2023 that its board of directors declared a regular quarterly dividend of $0.12 per share ($0.48 annualized). Shareholders of record as of March 9, 2023 will receive the payment on March 17, 2023. Previously, the company paid $0.12 per share.
At the current share price of $11.40 / share, the stock's dividend yield is 4.21%. Looking back five years and taking a sample every week, the average dividend yield has been 3.74%, the lowest has been 2.59%, and the highest has been 5.63%. The standard deviation of yields is 0.79 (n=105).
The current dividend yield is 0.59 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.28. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
Learn to Harvest Dividends
Buy Stock. Capture Dividend. Sell Stock. Repeat. This is the essence of dividend harvesting and you can do it easily with Fintel's Dividend Capture Calendar.
Analyst Price Forecast Suggests 20.34% Upside
As of March 1, 2023, the average one-year price target for Viatris is $13.72. The forecasts range from a low of $10.10 to a high of $18.90. The average price target represents an increase of 20.34% from its latest reported closing price of $11.40.
The projected annual revenue for Viatris is $16,163MM, a decrease of 0.61%. The projected annual EPS is $3.30, an increase of 92.68%.
What is the Fund Sentiment?
There are 1667 funds or institutions reporting positions in Viatris. This is an increase of 35 owner(s) or 2.14% in the last quarter. Average portfolio weight of all funds dedicated to VTRS is 0.21%, an increase of 14.69%. Total shares owned by institutions increased in the last three months by 1.62% to 1,028,540K shares. The put/call ratio of VTRS is 0.67, indicating a bullish outlook.
What are large shareholders doing?
Davis Selected Advisers holds 54,722K shares representing 4.51% ownership of the company. In it's prior filing, the firm reported owning 55,460K shares, representing a decrease of 1.35%. The firm increased its portfolio allocation in VTRS by 23.19% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 36,209K shares representing 2.99% ownership of the company. In it's prior filing, the firm reported owning 35,740K shares, representing an increase of 1.30%. The firm decreased its portfolio allocation in VTRS by 14.06% over the last quarter.
Price T Rowe Associates holds 32,611K shares representing 2.69% ownership of the company. In it's prior filing, the firm reported owning 28,575K shares, representing an increase of 12.38%. The firm increased its portfolio allocation in VTRS by 46.39% over the last quarter.
VIMSX - Vanguard Mid-Cap Index Fund Investor Shares holds 27,950K shares representing 2.30% ownership of the company. In it's prior filing, the firm reported owning 27,910K shares, representing an increase of 0.14%. The firm decreased its portfolio allocation in VTRS by 14.80% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 27,489K shares representing 2.27% ownership of the company. In it's prior filing, the firm reported owning 26,843K shares, representing an increase of 2.35%. The firm decreased its portfolio allocation in VTRS by 13.83% over the last quarter.
Viatris Background Information
(This description is provided by the company.)
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. It provides access to medicines, advance sustainable operations, develop innovative solutions and leverage its collective expertise to connect more people to more products and services through its one-of-a-kind Global Healthcare GatewayTM. Formed in November 2020through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghaiand Hyderabad, India.
This story originally appeared on Fintel.